Francesco Claps1,2,*, Miguel Ramírez-Backhaus1, Álvaro Gómez-Ferrer1, Juan Manuel Mascarós1, Argimiro Collado Serra1, Augusto Wong1, Ana Calatrava Fons3, Miguel Ángel Climent4, Antonio Amodeo2, Angelo Porreca5, Jose Rubio-Briones1,6
Canadian Journal of Urology, Vol.33, No.3, pp. 593-602, 2026, DOI:10.32604/cju.2025.070162
- 29 June 2026
Abstract Objectives: Residual Disease after adjuvant chemotherapy for non-seminomatous germ cell tumor (NSGCT) poses a significant clinical challenge and difficulties in tailored management. This study aimed to externally validate the Heidenreich criteria among patients eligible for unilateral post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for residual masses of NSGCT. Methods: For validation, these criteria were retrospectively applied in 23 patients undergoing PC-RPLND for residual masses of NSGCTs. In patients qualified for unilateral-modified PC-RPLND according to the Heidenreich criteria but treated with fully bilateral dissection, pathological reports were evaluated to identify teratoma or active cancer cells inside the… More >